Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ling Zou

Showing results (511-520 of 511) with videos related to

Pageof 52
Sort By:
You have reached the last page of results.This site can display upto 511 results.
Cancer Communications (London, England)|February 25, 2022
XELOX doublet regimen versus EOX triplet regimen as first-line treatment for advanced gastric cancer: An open-labeled, multicenter, randomized, prospective phase III trial (EXELOX)Xiao-Dong Zhu, Ming-Zhu Huang, Yu-Sheng Wang, et al.
Pageof 52

Showing results (511-520 of 511) with videos related to

Sort By:
Pageof 52
You have reached the last page of results.This site can display upto 511 results.
Cancer Communications (London, England)|February 25, 2022
XELOX doublet regimen versus EOX triplet regimen as first-line treatment for advanced gastric cancer: An open-labeled, multicenter, randomized, prospective phase III trial (EXELOX)Xiao-Dong Zhu, Ming-Zhu Huang, Yu-Sheng Wang, et al.
Pageof 52